The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS. The National Institute for Health and Care Excellence (Nice), which determines ...
After blasting the U.K.’s drug pricing policy, the pharma industry has secured a new government spending deal featuring a higher revenue cap and an innovative drug-friendly rebate mechanism. In a ...
A new UK drug approval pathway, designed to speed up the availability of new medicines, benefits industry over patients and ...
March 30 (Reuters) - Eli Lilly (LLY.N), opens new tab wants the UK to regularly raise NHS drug prices and phase out a multi-billion-pound rebate scheme if it is to resume investment, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results